Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Free fatty acid receptor 4 (FFA4) activation ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis by increasing regulatory T cells in mice

Abstract

High dose intake of docosahexaenoic acid showed beneficial effects on atopic dermatitis in patients and was found to increase regulatory T cells in mice, but its molecular target has not been identified. Free fatty acid receptor 4 (FFA4, also known as GPR120) is a receptor sensing polyunsaturated long-chain fatty acids including docosahexaenoic acid. In the present study, we examined whether FFA4 acted as a therapeutic target of docosahexaenoic acid for treating atopic dermatitis. Experimental atopic dermatitis was induced in mice by 2,4-dinitrochlorobenzene (DNCB) sensitization on day 0, followed by repeated DNCB challenges from D7 to D48. The mice were treated with a selective agonist compound A (30 mg· kg−1· d−1, ip) from D19 to D48, and sacrificed on D49. We found that DNCB-induced atopic dermatitis-like skin lesions, i.e. hypertrophy and mast cell infiltration in skin tissues, as well as markedly elevated serum IgE levels. Administration of compound A significantly suppressed the atopic responses in ears and lymph nodes, such as hypertrophy and mast cell infiltration in the ears, enlarged sizes of lymph nodes, and elevated serum IgE and levels of cytokines IL-4, IL-13, IL-17, and IFN-γ in ear tissue. The therapeutic effects of compound A were abolished by FFA4 knockout. Similarly, increased CD4+Foxp3+ regulatory T-cell population in lymph nodes was observed in wide-type mice treated with compound A, but not seen in FFA4-deficient mice. In conclusion, we demonstrate that activation of FFA4 ameliorates atopic dermatitis by increasing CD4+Foxp3+ regulatory T cells, suggesting FFA4 as a therapeutic target for atopic dermatitis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Experimental protocol for the induction of AD and the effect of compound A on DNCB-induced AD responses in the ears of FFA4 WT mice.
Fig. 2: Effect of compound A on the expression levels of the cytokines of Th2, Th1, and Th17 cells in the ear tissues of DNCB-induced AD FFA4 WT mice.
Fig. 3: Effect of compound A on DNCB-induced AD in the lymph nodes of FFA4 WT mice.
Fig. 4: Effect of compound A on the generation of CD4+Foxp3+ T cells in the lymph nodes of FFA4 WT mice.
Fig. 5: Effect of compound A on AD in the ears of FFA4 KO mice.
Fig. 6: Effect of compound A on the expression levels of Th2, Th1, and Th17 cytokines in the ear tissues of DNCB-induced AD FFA4 KO mice.
Fig. 7: Effect of compound A on DNCB-induced AD in the lymph nodes of FFA4 KO mice.
Fig. 8: Effect of compound A on the generation of CD4+Foxp3+ T cells in the lymph nodes of FFA4 KO mice.
Fig. 9: Compound A-induced activation of FFA4 in macrophages leads to M2 polarizarion.

References

  1. 1.

    Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Busse WW, et al. Report from the national institute of allergy and infectious diseases workshop on “atopic dermatitis and the atopic march: mechanisms and interventions”. J Allergy Clin Immunol. 2019;143:894–913.

    Article  Google Scholar 

  2. 2.

    Leung DY, Guttman-Yassky E. Assessing the current treatment of atopic dermatitis: unmet needs. J Allergy Clin Immunol. 2017;139:S47–8.

    Article  Google Scholar 

  3. 3.

    Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2012;129:879–86.

    CAS  Article  Google Scholar 

  4. 4.

    Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336–49.

    CAS  Article  Google Scholar 

  5. 5.

    Im DS. FFA4 (GPR120) as a fatty acid sensor involved in appetite control, insulin sensitivity and inflammation regulation. Mol Asp Med. 2018;64:92–108.

    CAS  Article  Google Scholar 

  6. 6.

    Ishihara T, Yoshida M, Arita M. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol. 2019;31:559–67.

    CAS  Article  Google Scholar 

  7. 7.

    Koch C, Dolle S, Metzger M, Rasche C, Jungclas H, Ruhl R, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol. 2008;158:786–92.

    CAS  Article  Google Scholar 

  8. 8.

    Han SC, Koo DH, Kang NJ, Yoon WJ, Kang GJ, Kang HK, et al. Docosahexaenoic acid alleviates atopic dermatitis by generating Tregs and IL-10/TGF-beta-modified macrophages via a TGF-beta-dependent mechanism. J Investig Dermatol. 2015;135:1556–64.

    CAS  Article  Google Scholar 

  9. 9.

    Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11:90–4.

    CAS  Article  Google Scholar 

  10. 10.

    Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–98.

    CAS  Article  Google Scholar 

  11. 11.

    Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharm Sci. 2011;32:543–50.

    CAS  Article  Google Scholar 

  12. 12.

    Moniri NH. Free-fatty acid receptor-4 (GPR120): cellular and molecular function and its role in metabolic disorders. Biochem Pharmacol. 2016;110–111:1–15.

    Article  Google Scholar 

  13. 13.

    Yore MM, Syed I, Moraes-Vieira PM, Zhang T, Herman MA, Homan EA, et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell. 2014;159:318–32.

    CAS  Article  Google Scholar 

  14. 14.

    Konno Y, Ueki S, Takeda M, Kobayashi Y, Tamaki M, Moritoki Y, et al. Functional analysis of free fatty acid receptor GPR120 in human eosinophils: implications in metabolic homeostasis. PLoS One. 2015;10:e0120386.

    Article  Google Scholar 

  15. 15.

    Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014;20:942–7.

    CAS  Article  Google Scholar 

  16. 16.

    Lee KP, Park SJ, Kang S, Koh JM, Sato K, Chung HY, et al. ω-3 Polyunsaturated fatty acids accelerate airway repair by activating FFA4 in club cells. Am J Physiol Lung Cell Mol Physiol. 2017;312:L835–44.

    Article  Google Scholar 

  17. 17.

    Kang S, Huang J, Lee BK, Jung YS, Im E, Koh JM, et al. Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120). Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:105–16.

    CAS  Article  Google Scholar 

  18. 18.

    Cox JM, Chu HD, Chelliah MV, Debenham JS, Eagen K, Lan P, et al. Design, synthesis, and evaluation of novel and selective G-protein coupled receptor 120 (GPR120) spirocyclic agonists. ACS Med Chem Lett. 2017;8:49–54.

    CAS  Article  Google Scholar 

  19. 19.

    Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108–16.

    CAS  Article  Google Scholar 

  20. 20.

    Ahn SH, Park SY, Baek JE, Lee SY, Baek WY, Lee SY, et al. Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. Endocrinology. 2016;157:2621–35.

    CAS  Article  Google Scholar 

  21. 21.

    Cho HJ, Ahn SH, Lee YS, Lee SH, Im DS, Kim I, et al. Free fatty acid receptor 4 mediates the beneficial effects of n-3 fatty acids on body composition in mice. Calcif Tissue Int. 2017;101:654–62.

    CAS  Article  Google Scholar 

  22. 22.

    Park SJ, Im DS. Blockage of sphingosine-1-phosphate receptor 2 attenuates allergic asthma in mice. Br J Pharmacol. 2019;176:938–49.

    CAS  Article  Google Scholar 

  23. 23.

    Voisin T, Chiu IM. Molecular link between itch and atopic dermatitis. Proc Natl Acad Sci USA. 2018;115:12851–3.

    CAS  Article  Google Scholar 

  24. 24.

    Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol. 2004;114:150–8.

    Article  Google Scholar 

  25. 25.

    Kim JY, Jeong MS, Park MK, Lee MK, Seo SJ. Time-dependent progression from the acute to chronic phases in atopic dermatitis induced by epicutaneous allergen stimulation in NC/Nga mice. Exp Dermatol. 2014;23:53–7.

    Article  Google Scholar 

  26. 26.

    Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Investig Dermatol. 2008;128:2625–30.

    CAS  Article  Google Scholar 

  27. 27.

    Muraro A, Lemanske RF Jr., Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European academy of allergy and clinical immunology and the American academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2016;137:1347–58.

    Article  Google Scholar 

  28. 28.

    Reynolds KA, Juhasz MLW, Mesinkovska NA. The role of oral vitamins and supplements in the management of atopic dermatitis: a systematic review. Int J Dermatol. 2019;58:1371–6.

    Article  Google Scholar 

  29. 29.

    Haitz KA, Anandasabapathy N. Docosahexaenoic acid alleviates atopic dermatitis in mice by generating T regulatory cells and m2 macrophages. J Investig Dermatol. 2015;135:1472–4.

    CAS  Article  Google Scholar 

  30. 30.

    Laidlaw M, Cockerline CA, Rowe WJ. A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. Lipids Health Dis. 2014;13:99.

    Article  Google Scholar 

  31. 31.

    Lin W, Truong N, Grossman WJ, Haribhai D, Williams CB, Wang J, et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol. 2005;116:1106–15.

    CAS  Article  Google Scholar 

  32. 32.

    Ma L, Xue HB, Guan XH, Shu CM, Wang F, Zhang JH, et al. The imbalance of Th17 cells and CD4+ CD25high Foxp3+ Treg cells in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28:1079–86.

    CAS  Article  Google Scholar 

  33. 33.

    Wannick M, Bezdek S, Guillen N, Thieme M, Meshrkey F, Mousavi S, et al. Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases. Pharmacol Res Perspect. 2018;6:e00438.

    Article  Google Scholar 

  34. 34.

    Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Asp Med. 2017;58:114–29.

    CAS  Article  Google Scholar 

  35. 35.

    Im DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res. 2012;51:232–7.

    CAS  Article  Google Scholar 

  36. 36.

    Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201:713–22.

    CAS  Article  Google Scholar 

  37. 37.

    Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA. 2010;107:1660–5.

    CAS  Article  Google Scholar 

  38. 38.

    Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015;212:1203–17.

    CAS  Article  Google Scholar 

  39. 39.

    Qu L, Caterina MJ. Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37. J Clin Investig. 2018;128:3246–9.

    Article  Google Scholar 

  40. 40.

    Chiang N, Libreros S, Norris PC, de la Rosa X, Serhan CN. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J Clin Investig. 2019;129:5294–311.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This research was supported by the Basic Science Research Program of the Korean National Research Foundation, which is funded by the Korean Ministry of Education, Science and Technology (NRF-2019R1A2C1005523).

Author information

Affiliations

Authors

Contributions

SES, JMK, and DSI designed the experiments. SES and SJP performed the experiments and analyzed the data. SES and DSI wrote the paper.

Corresponding author

Correspondence to Dong-Soon Im.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Son, SE., Park, SJ., Koh, JM. et al. Free fatty acid receptor 4 (FFA4) activation ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis by increasing regulatory T cells in mice. Acta Pharmacol Sin 41, 1337–1347 (2020). https://doi.org/10.1038/s41401-020-0435-1

Download citation

Keywords

  • atopic dermatitis
  • 2,4-dinitrochlorobenzene
  • free fatty acid receptor 4
  • FFA4 agonist
  • polyunsaturated fatty acids
  • Omega-3
  • Treg cells
  • skin

Further reading

Search

Quick links